Valye reports for unlimited access

Nocopi Technologies, Inc. is a specialty ink formulator focused on reactive inks used in entertainment and toy products and in anti-counterfeiting and anti-diversion applications. The company’s patented technologies, including Rub & Reveal and Rub-It & Color, provide unique ink formulations that are safe, non-toxic, and designed for specific customer needs. Revenues are primarily derived from licensing agreements and product sales to licensees and their printers. The company operates a manufacturing facility in King of Prussia, Pennsylvania, and maintains a portfolio of patents across multiple countries. Nocopi’s business is concentrated with a small number of major customers and is subject to fluctuations based on license renewals and market conditions. The company pursues growth through strategic acquisitions, including the recent acquisition of Polymeric U.S., Inc., which expanded its product offerings and manufacturing capabilities. Research and development efforts focus on refining existing products, developing customer applications, and expanding technology applications.

Forefront Tech Holdings Acquisition Corp is a Cayman Islands-based special purpose acquisition company (SPAC) that completed its initial public offering (IPO) on May 1, 2026. The IPO raised gross proceeds of approximately $100 million through the issuance of 10 million units, each consisting of one Class A ordinary share and one-half of one redeemable warrant. The company also completed a private placement raising an additional $3.7 million. The proceeds from the offering are held in a trust account and are subject to release conditions tied to the completion of an initial business combination or other shareholder-approved events. The company is listed on the Nasdaq Stock Market under the tickers FTHA (Class A shares), FTHAU (units), and FTHAW (warrants).

PetMed Express, Inc., founded in 1996, operates as a leading nationwide direct-to-consumer pet pharmacy and wellness retailer under the brands PetMeds and PetCareRx. The company offers a broad product range including prescription medications, generic and compounded prescriptions, OTC health products, premium pet foods, and supplies for dogs, cats, and horses. It operates licensed pharmacies in Lynbrook, NY and Delray Beach, FL, staffed by licensed pharmacists and compliant with federal and state regulations. The company markets and sells primarily through its websites, mobile apps, a customer contact center, and the PetAssure broker network targeting employer pet health benefits. It emphasizes customer care, personalized digital experiences, and AutoShip subscription services. The company sources inventory directly from manufacturers and FDA-registered distributors, managing fulfillment in-house. Recent strategic initiatives focus on technology modernization, loyalty programs, and expanding B2B pharmacy fulfillment partnerships.

Quantum-Si Inc is a technology company focused on developing the Proteus platform, a product intended for applications in life sciences. The company has experienced delays in the commercial launch of Proteus, moving the anticipated availability from the end of 2026 to the second quarter of 2027 due to development challenges. Financially, the company reported a net loss in the second quarter of 2026 but holds substantial liquidity with a current ratio near 10 and a cash ratio above 26 as of June 30, 2026. The company is currently under Nasdaq compliance review due to its stock price falling below the minimum bid price requirement.

Lument Finance Trust, Inc. operates as a real estate investment trust (REIT) specializing in commercial real estate debt investments. The company focuses on originating and managing transitional floating rate commercial mortgage loans, primarily secured by middle-market multifamily properties. It also invests in mezzanine loans, preferred equity, CMBS, fixed rate loans, construction loans, and other CRE-related debt instruments. The company is externally managed by Lument Investment Management, LLC, affiliated with ORIX Corporation USA. The portfolio as of late 2025 includes over $1.1 billion in senior secured floating rate loans, predominantly multifamily, with a weighted average coupon of 7.2%. The company employs leverage through various financing arrangements including collateralized loan obligations and repurchase agreements. It is subject to competition from other financial institutions and REITs and integrates sustainability considerations into its investment and operational practices.

DirectBooking Technology Co., Ltd. is a Cayman Islands-incorporated company with a Hong Kong subsidiary. The company reported revenues of approximately $8.9 million USD and a net loss of about $13.3 million USD for the fiscal year ending March 31, 2026. It holds current assets of roughly $16.9 million USD against current liabilities of $4.3 million USD, resulting in a current ratio of 3.9. The company had a significant investment agreement to acquire a 49% stake in China Wangmao Liquor Industry Group Co., Limited, which was terminated with compensation agreed upon. The company’s shares are listed on the Nasdaq Capital Market under the ticker ZDAI, following a ticker symbol change effective May 16, 2025.

First Choice Healthcare Solutions, Inc. is a Delaware corporation that historically operated orthopedic and physical therapy services but is now pivoting to develop a national chain of medical functional health and wellness clinics. The new strategy focuses on life improvement services such as anti-aging, hormone replacement therapy, weight management, and pharmacy services, primarily delivered through nurse practitioners to improve margins. The company has acquired several entities including LiveWell Drugstore, a compounding pharmacy, and The Good Clinic, a primary care clinic concept. The business model integrates personalized care plans with internal pharmacy and diagnostic services to provide a comprehensive healthcare experience. The company exited bankruptcy in 2022 and is restructuring its operations to focus on growth in the wellness and primary care market [S1].

XCel Brands, Inc. is a Delaware-incorporated company trading on the NASDAQ Capital Market under the ticker XELB. The company operates in the branded consumer products sector, with recent initiatives including launching smart pet product lines and partnerships with known personalities such as Cesar Millan. The company has a history of quarterly losses and revenue shortfalls as reported in recent earnings and news coverage. Financial filings show liquidity constraints with current liabilities significantly exceeding current assets as of mid-2026. The company actively manages its capital structure through amendments to loan agreements and senior secured note issuances.

WEN Acquisition Corp is a Cayman Islands exempted blank check company formed in January 2025 to pursue a Business Combination with one or more businesses, primarily targeting fintech infrastructure companies focused on digital assets and blockchain integration. The company completed its IPO in May 2025, raising approximately $300 million, and has placed the proceeds in a Trust Account. It has not yet selected a Business Combination target and has no operating revenues. The management team has significant experience in fintech and SPAC transactions.

LIVE VENTURES Inc is a publicly traded company incorporated in Nevada, United States, with principal offices in Las Vegas. The company reports financial results quarterly and annually through SEC filings, including 10-K and 10-Q forms. As of June 30, 2026, the company held $10.9 million in cash and cash equivalents and had a current ratio of 1.35, indicating liquidity above current liabilities. The company reported a net loss of approximately $1.06 million for the quarter ended June 30, 2026, with negative earnings per share of $0.34. LIVE VENTURES communicates regularly with investors through earnings releases and conference calls, with recent coverage highlighting revenue growth despite challenges and amendments to executive employment agreements.

Global Gas Corporation is a Delaware-based company specializing in hydrogen and carbon recovery project development and industrial gas supply. Founded in 2023 through a business combination, the company focuses on producing low-carbon and clean hydrogen, pure carbon dioxide, and other gases from renewable waste and non-renewable feedstocks. Its business model includes sourcing and vetting offtake customers, securing feedstocks and equipment, project planning and management, and project financing. The company targets traditional industrial gas customers and the emerging hydrogen-as-energy-carrier market, particularly for heavy-duty transportation fleets. It aims to deploy modular generation and recovery systems close to end customers to reduce distribution costs and leverage government incentives such as the U.S. Inflation Reduction Act. As of mid-2026, Global Gas has a limited operating history, no significant revenue, and two full-time employees. The company sources equipment globally and may provide engineering and operational services related to its projects.

Avidity Biosciences, Inc. focuses on developing a novel class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), which combine monoclonal antibodies with RNA therapeutics to target diseases previously untreatable by such methods. The company’s pipeline includes three clinical-stage programs: del-zota for Duchenne muscular dystrophy (DMD44), del-desiran for myotonic dystrophy type 1 (DM1), and del-brax for facioscapulohumeral muscular dystrophy (FSHD). These programs have received multiple orphan and expedited regulatory designations. The company has initiated a Managed Access Program for del-zota in the U.S. In October 2025, Avidity entered into a merger agreement with Novartis AG, with a planned spin-off of its early stage precision cardiology programs into a separate entity, Atrium Therapeutics, Inc. The merger and spin-off are subject to customary closing conditions and regulatory approvals, with expected completion in the first half of 2026. The company reported a net loss of $684.6 million for fiscal 2025 and maintains strong liquidity with a current ratio of 9.2 as of December 31, 2025.

Concord Acquisition Corp II is a Delaware-incorporated special purpose acquisition company (SPAC) trading on OTC Pink markets under the ticker CNDA. The company issues Class A common stock, units, and warrants. It is an emerging growth company and has extended its deadline to complete a business combination to December 31, 2025. The company reported net income and liquidity metrics as of June 30, 2026, but detailed operational or business model information is not disclosed in the filings reviewed.

Bogota Financial Corp. serves as the bank holding company for Bogota Savings Bank, which operates primarily in New Jersey with a focus on one- to four-family residential real estate loans, commercial real estate, and multi-family real estate loans. The bank's loan portfolio is diversified across fixed and adjustable-rate loans, with underwriting standards aligned with Fannie Mae and Freddie Mac guidelines for residential loans and conservative loan-to-value ratios for commercial loans. The company completed a mutual holding company reorganization in 2019 and a stock offering in 2020. It faces significant competition from larger banks, credit unions, and non-depository financial service providers. The company is subject to comprehensive regulatory oversight.

KinderCare Learning Companies, Inc. operates in the education and training services sector, providing learning services. The company regularly files SEC reports and holds earnings calls that are publicly accessible. Its financial snapshot as of mid-2026 shows a liquidity position with cash and equivalents of $173.7 million and current liabilities exceeding current assets, resulting in a current ratio below 1. The company reported a net loss and negative earnings per share for Q2 2026. Recent news coverage focuses on its quarterly earnings performance and sector positioning.

Summit Networks Inc. was incorporated in 2014 and historically explored various business opportunities without sustained revenues. In 2025, it completed internal development activities focused on organizational and governance improvements. The company is now in a strategic transition phase aiming to acquire controlling interests in cash-flow generating logistics businesses, primarily in Asia. It seeks to build a scalable platform through disciplined acquisitions rather than organic growth. The company faces a highly competitive and fragmented logistics industry and relies on shareholder support and cost control to maintain liquidity. As of mid-2026, it has no committed financing or acquisition agreements and reports as a single operating segment [S1][S2].

Yubo International Biotech Ltd is a publicly traded company with limited publicly available information on its business model, industry classification, or geographic base beyond references to PRC and Hong Kong subsidiaries. The company reported no revenue and a net loss in its latest quarterly filing. It faces regulatory risks under U.S. and PRC laws, including audit inspection requirements under the Holding Foreign Companies Accountable Act and complex PRC tax and foreign exchange regulations. Liquidity metrics indicate current liabilities substantially exceed current assets as of mid-2026. Recent news items associated with the ticker relate to agricultural commodity markets and dividend runs of unrelated companies, providing no insight into the company’s operations.

Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in therapies for pulmonary fibrosis, with a focus on idiopathic pulmonary fibrosis (IPF). The company rebranded from Aileron Therapeutics in early 2025 to reflect this strategic focus. Its lead drug candidate, LTI-03, has demonstrated positive Phase 1b clinical data and is currently in Phase 2 clinical trials, with FDA clearance to resume these trials received in late 2025. Rein has actively communicated enrollment progress for its Phase 2 RENEW study. The company operates with a governance structure featuring a staggered board of directors and committees overseeing key functions. Financially, Rein is in the clinical development stage with no reported revenues, maintaining liquidity through recent equity offerings and promissory notes.

Nevada Canyon Gold Corp. operates as a junior mineral exploration company with a focus on acquiring, exploring, and developing gold and precious metal properties in the United States. Its portfolio includes interests in the Loman and Agai-Pah properties in Nevada and the Belshazzar property in Idaho. The company primarily holds passive royalty, streaming, and similar interests rather than operating mines directly. None of its properties are currently producing, and the company has no established mineral reserves. The business model depends on the exploration and development activities of third-party operators, over which Nevada Canyon Gold has limited control. The company has a limited operating history and has sustained losses since inception, requiring ongoing financing to support its exploration and development activities. It faces risks common to early-stage mining companies, including operational, financial, regulatory, and market risks.

SPACSphere Acquisition Corp. operates as a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. Its business model is to identify and complete an initial business combination with one or more target companies, which may be in any industry or geographic region. The company completed its IPO in February 2026, issuing public units consisting of Class A ordinary shares, warrants, and rights, raising gross proceeds of $172.5 million, plus a private placement. The proceeds are held in a trust account invested in U.S. government treasury bills or money market funds. The company has not yet selected a target but has defined acquisition criteria emphasizing competitive position, management quality, growth potential, and risk-adjusted returns. The management team has extensive experience and networks to source potential targets. The company intends to complete the business combination within 15 months of the IPO, with possible extensions. Recent developments include a proposed business combination with Mobilewalla, a provider of data-centric, vertical agentic AI solutions, with a registration statement filed on Form S-4.

TOP Financial Group Ltd is a financial services company operating a single reportable segment. Its business model includes futures brokerage commissions, virtual asset brokerage commissions, trading solution services fees, and other financial services such as securities brokerage and currency exchange. Revenues are recognized based on the nature of the service, with virtual asset brokerage commissions recognized at trade date and trading solution services recognized over time. The company maintains segregated client accounts for customer funds and holds cash in banks across Hong Kong, Singapore, and Australia. It has completed acquisitions to expand its licensed financial services operations, including entities in the British Virgin Islands, Australia, and Hong Kong. Customer concentration is significant, with two customers accounting for a substantial portion of revenue. The company reported a net loss for the recent quarter and maintains a moderate level of cash and cash equivalents.

XCF Global, Inc. operates in the renewable energy sector, specializing in sustainable aviation fuel (SAF) and renewable diesel production. The company has announced a significant $1 billion investment plan aimed at expanding SAF production capacity in the U.S. and globally. XCF Global is engaged in business combination transactions with DevvStream Corp. and Southern Energy Renewables Inc., which are subject to customary closing conditions. The company has a leadership team with extensive experience in energy and finance. Financially, XCF Global reported modest revenue and a substantial net loss in the first half of 2026, with liquidity challenges indicated by a low current ratio. The company faces operational and legal risks, including disputes with Phillips 66 and uncertainties related to the completion of business combination transactions.

FDCTech, Inc. specializes in developing and delivering innovative software solutions and business services to the OTC brokerage and financial services industries. Its flagship product is the Condor Trading Technology suite, supporting multi-asset trading and risk management. The company has expanded globally through acquisitions, operating subsidiaries in Australia, Europe, the UK, Seychelles, and Mauritius. It serves retail and institutional clients with multi-asset trading services, wealth management advisory, proprietary trading technology licensing, and is developing payment intermediary services. The company aims to provide integrated, plug-and-play brokerage solutions combining technology, regulatory licenses, liquidity, and digital payment rails to address structural market barriers.

Wellgistics Health, Inc. operates in the pharmaceutical supply chain and digital health sector, focusing on improving transparency, efficiency, and cost benefits for US pharmaceutical channel partners. The company offers pharmacy solutions and has engaged in partnerships and joint ventures to expand patient access and market novel medical foods addressing specific health conditions. It has achieved SOC 2 Type 1 compliance, underscoring its commitment to data security and regulatory standards. The company completed its IPO and Nasdaq listing in early 2025.

Evolution Metals & Technologies Corp. is a holding company with operations conducted through its subsidiary Evolution Metals LLC and Korean subsidiaries. The company focuses on building a U.S.-aligned supply chain for critical minerals and materials, including rare earth elements and battery materials, primarily through recycling end-of-life materials such as batteries, electronic devices, and magnets. Its vertically integrated platform spans feedstock processing, oxide production, metal and alloy manufacturing, powder production, magnet manufacturing, and battery-grade material production. EM&T is developing a large-scale U.S. industrial campus to co-locate recycling, refining, and manufacturing operations, aiming to improve operational efficiency and supply chain security. The company integrates AI and automation technologies to optimize production and serves customers in automotive, renewable energy, consumer electronics, and defense sectors. Financially, as of June 30, 2026, EM&T reported revenue of $1.636 million and a net loss of $11.91 million, with liquidity ratios indicating limited short-term liquidity [S1][S2].

Regen BioPharma Inc is a Nevada-incorporated company focused on developing regenerative medical therapies. Its business model centers on advancing therapies through early clinical trial phases (Phase I/II) and then either licensing, selling, or further developing these therapies. The company has multiple product candidates in development targeting conditions such as aplastic anemia and various cancers, utilizing cellular therapies, siRNA, CAR-T cells, and small molecule modulators. It holds several patents related to gene silencing and immune modulation technologies. Revenue is primarily derived from licensing agreements with upfront fees, royalties, and sublicensing income. The company expenses research and development costs as incurred and recognizes royalty revenue based on licensee sales estimates.

NEXGEL, INC. operates in the regenerative biomaterials sector, focusing on commercial-stage products under its BioNx brand acquired through an exclusive license from Celularity. The company is led by CEO Adam Levy and CFO Ian Blackman, with a board comprising experienced professionals in finance, biotech, and capital markets. NEXGEL has demonstrated significant revenue growth in recent years, including over 100% growth in 2024 and doubling revenue in fiscal Q2 2025. The company’s financial position as of mid-2026 shows a net loss and liquidity challenges, with current liabilities exceeding current assets. The company has issued convertible notes in 2026, which may impact liquidity and shareholder dilution. NEXGEL continues to expand partnerships and product offerings, including collaborations with STADA Arzneimittel AG and licensing agreements for biomaterial products.

Generation Income Properties, Inc. is a real estate investment company focused on net lease commercial properties. It holds a portfolio of income-producing properties, including those acquired through a special purpose entity (GIP SPE). The company’s business model involves acquiring, managing, and potentially selling real estate assets to generate rental income. It faces liquidity challenges and has significant debt obligations due in the near term. The company is publicly listed on Nasdaq and has recently addressed compliance issues related to listing standards. Leadership includes experienced real estate and finance professionals, with the founder and CEO having a strong background in net lease real estate.

Yinfu Gold Corporation is a Wyoming corporation incorporated in 2005, with its business office located in Shenzhen, China. Initially an exploration stage company focused on mineral resources, it ceased mineral exploration activities and shifted its business model around 2010. The company acquired China Enterprise Overseas Investment & Finance Group Limited and its assets, including a large customer database, in 2014. It has not generated revenue to date and has sustained operating losses, relying on capital injections from directors and stockholders. The company has limited cash and current assets but significant current liabilities, resulting in a very low liquidity position. It employs three people, including its president and chairman, and plans to hire additional staff when financially able. The company is subject to general business laws and evolving PRC regulations that may impact its operations.

Extreme Networks Inc operates in the networking technology sector, focusing on advanced networking solutions including AI-driven platforms and next-generation Wi-Fi technologies such as Wi-Fi 7. The company targets enterprise and government customers with its AI platform to enhance network automation and performance. Recent earnings reports indicate operational progress with revenues and earnings surpassing prior quarters. The company maintains a significant cash position but has a current ratio below 1, indicating current liabilities slightly exceed current assets as of June 30, 2026.

Ming Shing Group Holdings Ltd is a foreign private issuer listed on Nasdaq, with a board comprising both independent and non-independent directors. The company has undergone recent leadership changes, with Mr. Pan appointed CEO and chairman in 2026. It engages in strategic acquisitions, notably the planned acquisition of Meals Through Seasons Limited, a company involved in organic agricultural product supply chains and related businesses. The acquisition consideration involves issuance of shares and convertible promissory notes subject to performance conditions, which will dilute existing shareholders. The company has disclosed employment agreements with executives that include confidentiality and non-compete provisions. Financially, the company reported a net loss and liquidity ratios below 1 as of March 31, 2026. Recent operational news includes revenue growth and investment in Bitcoin, alongside periods of trading halts and resumptions.

DSwiss Inc is a Nevada-based biotech nutraceutical company operating through subsidiaries in Seychelles, Hong Kong, and Malaysia. The company specializes in premium health and beauty products, including functional foods, health supplements, skincare, personal care, and pet wellness products. It offers turnkey private label manufacturing (OEM/ODM) services encompassing formulation R&D, manufacturing, packaging, shipping, and regulatory compliance. DSwiss emphasizes natural ingredients, rigorous quality control, and adherence to international standards such as GMP and Halal certifications. The company has expanded its workforce with industry experts and maintains a strong distributor network across Asia-Pacific, while actively pursuing global market expansion and strategic mergers and acquisitions. Financially, as of June 30, 2026, DSwiss reported a net loss and liquidity ratios below 1, indicating current liabilities exceed current assets. The company is focused on innovation, sustainability, and enhancing brand visibility through digital marketing and trade show participation.

Irenic Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in March 2026. The company’s business model is to raise capital through an initial public offering and then seek to acquire or merge with an operating business (Business Combination). The company completed its IPO in April 2026, issuing units consisting of Class A ordinary shares and redeemable warrants. It also completed a private placement with its Sponsor and underwriters. The proceeds from the IPO and related offerings are held in a Trust Account invested in money market funds backed by U.S. Treasury securities. The company has not generated operating revenues and currently earns interest income on the Trust Account investments. It has administrative agreements with its Sponsor for office and administrative services. The company is classified as an emerging growth company and smaller reporting company, with certain regulatory exemptions. It has a defined period (Completion Window) to complete its initial Business Combination, after which it may liquidate and return funds to shareholders if no combination is completed.

Lakewood-Amedex Biotherapeutics Inc. is a biotechnology company developing Bisphosphocin® compounds, a novel class of fast-acting, broad-spectrum antimicrobials aimed at addressing drug-resistant infections and antimicrobial resistance. Its lead clinical program, Nu-3, is a topical antimicrobial gel in clinical development for infected diabetic foot ulcers. The company is publicly traded on Nasdaq under the ticker LABT and is classified as a smaller reporting and emerging growth company. It has recently appointed an experienced biotech executive to its board and has disclosed clinical progress and resistance data supporting its development programs.

Cartesian Growth Corp II is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in October 2021. Its purpose is to effectuate a merger or similar business combination with one or more target companies, focusing on high-growth businesses with transnational potential. The company raised gross proceeds of $230 million in its IPO in May 2022, placing most funds in a trust account to be used for the business combination or redemptions. It has not commenced operations or generated revenues and has incurred net losses related to operating and formation costs. The company’s securities were delisted from Nasdaq in May 2025 due to failure to complete a business combination within the prescribed timeframe and now trade on the OTC Pink market. The company has extended its deadline to complete a business combination multiple times, with the current deadline set for August 5, 2026. It faces liquidity challenges and substantial doubt about its ability to continue as a going concern without completing a business combination or securing additional capital.

NewHold Investment Corp IV is a blank check company formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. Incorporated in the Cayman Islands, the company completed its initial public offering on April 16, 2026, issuing units consisting of Class A ordinary shares and redeemable warrants. The proceeds from the IPO and private placement are held in a trust account until the completion of an initial business combination or other specified events. The company has no operations of its own and relies on third-party service providers for technology and administrative functions.